The insider sales are routine post-earnings option-exercise transactions, not a bearish signal. The CMO sold 100% of his exercisable options, which is typical for liquidity/diversification. Monitor for any Form 4 filings from the CEO or CFO in the coming weeks—C-suite sales would carry more weight. The ongoing patent litigation with United Therapeutics remains the primary catalyst for LQDA.
Price Chart
Executive Summary
Two insiders at Liquidia Corp sold a combined $6.46M in open-market sales within a week of the company's Q2 2026 earnings report. The sales are predominantly option-exercise-and-sell transactions by a director and the Chief Medical Officer, executed at prices near $72-$77, representing approximately 0.1% of the company's $6.4B market cap. While the dollar amount is modest relative to market cap, the cluster timing—just 10 days after a bullish earnings report—and the involvement of the CMO suggest these are routine post-earnings window sales rather than a bearish signal, though the volume is notable for a single director's sales exceeding $4M.
Key Financial Metrics
Key Facts
- Two insiders sold a combined $6.46M in open-market sales over a 7-day window.
- Director Katherine Rielly-Gauvin sold 55,182 shares for ~$4.09M; CMO Rajeev Saggar sold 79,534 shares for ~$5.97M.
- All sales were preceded by option exercises at nominal strike prices ($0-$3.73), indicating tax-motivated cash-out transactions.
- Sales occurred 10 days after Q2 2026 earnings (net income $74.7M, product sales $170.4M) and within the post-earnings trading window.
- Total open-market sales represent ~0.1% of Liquidia's $6.4B market cap—below the 0.5% threshold for material insider selling.
Financial Impact
Total insider sales of $6.46M represent 0.1% of market cap—immaterial from a capital markets perspective.
Risk Factors
- Insider sales could accelerate if the stock continues its post-earnings rally, adding near-term selling pressure.
- The patent litigation over Yutrepia (injunctive relief sought by United Therapeutics) remains unresolved and could materially impact the stock.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-LQDA-1787379401715 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | 8-K | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $43.74 (+28.87%) |
Oct 13, 2026 12d ago | Insider Cluster | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $43.74 (+28.87%) |
Sep 30, 2026 25d ago | 8-K | $27.99 $28.64 | ▼ −2.32% | ▼ −1.58% | $43.74 (−56.27%) |
Sep 3, 2026 7w ago | 8-K | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $43.74 (−36.27%) |
Sep 3, 2026 7w ago | Press Release | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $43.74 (−36.27%) |
Aug 25, 2026 8w ago | Insider Cluster | $71.36 $69.94 | ▼ −1.99% | ▼ −2.65% | $43.74 (−38.71%) |
Aug 21, 2026 9w ago | Insider Cluster | $70.27 $70.49 | ▲ +0.31% | ▼ −0.01% | $43.74 (−37.75%) |
Aug 12, 2026 10w ago | 8-K | $78.79 $72.10 | ▼ −8.49% | ▼ −9.19% | $43.74 (−44.49%) |
Aug 12, 2026 10w ago | Press Release | $78.79 $72.10 | ▲ +8.49% | ▲ +9.19% | $43.74 (+44.49%) |
Jul 29, 2026 12w ago | Insider Cluster | $86.80 $84.11 | ▼ −3.10% | ▼ −3.82% | $43.74 (−49.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers